Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women

DISEASE CHARACTERISTICS: * Increased risk for breast cancer on the basis of at least 1 of the following criteria: * Five-year Gail risk at least 1.7% or a calculated risk at least 5 times the average for age group * 20-29 years old - calculated 5-year Gail risk is at least 0.1% * 30-39 years old - calculated 5-year Gail risk is at least 1.0% * 40 and over - calculated 5-year Gail risk is at least 1.7% * Known BRCA1/BRCA2 mutation carrier * Family history consistent with hereditary breast cancer, as defined by any of the following circumstances: * At least 4 relatives with breast cancer at any age * At least 2 first-degree relatives diagnosed with breast cancer at age 50 or younger * Breast and ovarian cancer diagnosed in the same relative * At least 2 occurrences of breast cancer and 1 occurrence of ovarian cancer at any age in the same family * Prior biopsy exhibiting atypical hyperplasia, lobular cancer in situ, ductal carcinoma in situ (DCIS)\*, or invasive cancer\*\* NOTE: \*If DCIS or T1a or T1b disease was found, at least 2 months must have elapsed since prior surgery and/or radiotherapy to the involved breast NOTE: \*\*Prior invasive cancer (T1c, T2, or T3) must have been diagnosed at least 2 years before study and be estrogen receptor-negative, node negative * Must have had a random periareolar fine needle aspiration successfully performed within the past 3 months, with at least 1,000 cells on cytology slide and 3 additional slides for biomarker analysis (1 with at least 500 cells for Ki-67 and 2 with at least 100 ductal cells for estrogen receptors and COX-2) * Hormone receptor status: * Estrogen receptor negative PATIENT CHARACTERISTICS: Age * 18 to 55 Sex * Female Menopausal status * Premenopausal, defined as menstrual periods estimated to occur every 21 to 35 days over the past 6 months Performance status * Not specified Life expectancy * At least 5 years Hematopoietic * Absolute granulocyte count at least 1,000/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin at least 10 g/dL * No bleeding diathesis within the past year Hepatic * Bilirubin no greater than 2.0 mg/dL * Albumin at least 3.0 g/dL * AST and ALT no greater than 2 times upper limit of normal (ULN) * Alkaline phosphatase no greater than 2 times ULN * No severe liver disease requiring treatment Renal * Creatinine no greater than 1.5 mg/dL Cardiovascular * No high blood pressure not controlled by medication * No history of angina * No history of cardiovascular disease * No history of deep vein thrombosis Pulmonary * No history of pulmonary embolism Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No prior allergy to sulfa, COX-2 inhibitors, or nonsteroidal anti-inflammatory drugs (NSAIDs) * No history of an ulcer requiring treatment * No history of ulcerative colitis * No inflammatory bowel disease * No body mass index \> 33 * No history of diabetes * No prior metastatic malignancy of any kind * No complications of alcoholism requiring hospitalization * No concurrent asthma being treated PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * At least 6 months since prior chemotherapy Endocrine therapy * At least 6 months since prior antihormone therapy (e.g., selective estrogen-receptor modulators or aromatase inhibitors) * Anticipated use of oral or IV corticosteroids must be less than 2 weeks per year * No change (stop or start) in hormonal therapy within the past 6 months (e.g., estrogen, progesterone, oral contraceptives, or fertility agents) Radiotherapy * See Disease Characteristics * No prior radiotherapy to the contralateral breast involved in the study treatment Surgery * See Disease Characteristics Other * At least 3 weeks since prior aspirin, rofecoxib, celecoxib, other COX-2 inhibitors, or NSAIDs * No concurrent anticoagulants * No other concurrent NSAIDs * No chronic angiotensin-converting enzyme inhibitors * No chronic furosemide\* * No chronic fluconazole\* * No chronic lithium NOTE: \*Occasional concurrent use allowed